🇪🇺 InductOs in European Union

EMA authorised InductOs on 9 September 2002

Marketing authorisation

EMA — authorised 9 September 2002

  • Application: EMEA/H/C/000408
  • Marketing authorisation holder: Medtronic BioPharma B.V.
  • Local brand name: Inductos
  • Indication: Inductos is indicated for single level lumbar interbody spine fusion as a substitute for autogenous bone graft in adults with degenerative disc disease who have had at least 6 months of non operative treatment for this condition. Inductos is indicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation.
  • Status: approved

Read official source →

InductOs in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is InductOs approved in European Union?

Yes. EMA authorised it on 9 September 2002.

Who is the marketing authorisation holder for InductOs in European Union?

Medtronic BioPharma B.V. holds the EU marketing authorisation.